Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus

American Journal of Cardiology

Volumn 90, Issue 11, 2002, Pages 1254-1257

  Playford, David A ^a   Watts, Gerald F ^a,b   Best, James D ^a   Burke, Valerie ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CREATINE KINASE; CREATININE; FENOFIBRATE; GLUCOSE; GLYCERYL TRINITRATE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MUSCLE ENZYME; PLACEBO; TRIACYLGLYCEROL; URIC ACID;

ARTERY BLOOD FLOW; ARTERY DIAMETER; ARTERY DILATATION; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DOPPLER FLOWMETER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSLIPOPROTEINEMIA; ENDOTHELIUM; ENZYME BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEART RATE; HEMOGLOBIN DETERMINATION; HUMAN; IMAGE ANALYSIS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LINEAR REGRESSION ANALYSIS; LIPID ANALYSIS; LIPID DIET; MUSCLE LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; URTICARIA; VENOUS BLOOD; VIDEORECORDING;

ANTILIPEMIC AGENTS; BRACHIAL ARTERY; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PROCETOFEN; REGIONAL BLOOD FLOW; RISK FACTORS; TREATMENT OUTCOME; VASODILATION;

EID: 0036890093     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02847-3     Document Type: Article

References (20)

1. Watts G.F., O'Brien S.F., Silvester W., Millar J.A. Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin- dependent diabetes role of dyslipidaemia . Clin Sci (Colch). 91:1996;567-573.
2. Watts G.F., Playford D.A. Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus an hypothesis . Atherosclerosis. 141:1998;17-30.
3. Watts G.F., Dimmitt S.B. Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol. 10:1999;561-574.
4. Diabetes Atherosclerosis Intervention Study Investigators . Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes the Diabetes Atherosclerosis Intervention Study, a randomised study . Lancet. 357:2001;905-910.
5. Fruchart J.C., Duriez P., Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opinion Lipidol. 10:1999;245-257.
6. Playford D.A., Watts G.F. Special article - non-invasive measurement of endothelial function. Clin Exp Pharmacol Physiol. 25:1998;640-643.
7. Woodman R.J., Playford D.A., Watts G.F., Cheetham C., Reed C., Taylor R.R., Puddey I.B., Beilin L.J., Burke V., Mori T.A., Green D. Improved analysis of brachial artery ultrasound using a novel edge-detection software system. J App Physiol. 91:2001;929-937.
8. Mori T.A., Croft K.D., Puddey I.B., Beilin L.J. An improved method for the measurement of urinary and plasma F2-isoprostanes using gas chromatography mass spectrometry. Anal Biochem. 268:1999;117-125.
9. De Vriese AS, Verbeuren TJ, Van der Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol 2000;130:963-974.
10. Anderson R.A., Evans M.L., Ellis G.R., Graham J., Morris K., Jackson S.K., Lewis M.J., Rees A., Frenneaux M.P. The relationships between post-prandial lipaemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes. Atherosclerosis. 154:2001;475-483.
11. O'Brien S.F., Watts G.F., Playford D.A., Burke V., O'Neal D.N., Best J.D. Low-density lipoprotein size, high-density lipoprotein concentration, and endothelial dysfunction in non-insulin-dependent diabetes. Diabetic Med. 14:1997;974-978.
12. Evans M., Anderson R.A., Graham J., Ellis G.R., Morris K., Davies S., Jackson S.K., Lewis M.J., Frenneaux M.P., Rees A. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation. 101:2000;1773-1779.
13. Wilmink H.W., Twickler M.B., Banga J.D., Dallinga-Thie G.M., Eeltink H., Erkelens D.W., Rabelink T.J., Stroes E.S. Effect of statin versus fibrate on postprandial endothelial dysfunction role of remnant-like particles . Cardiovasc Res. 50:2001;577-582.
14. Avogaro A., Miola M., Favaro A., Gottardo L., Pacini G., Manzato E., Zambon S., Sacerdoti D., de Kreutzenberg S.V., Piliego T., Tiengo A., Del Prato S. Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. Eur J Clin Invest. 31:2001;603-609.
15. Seiler C., Suter T.M., Hess O.M. Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. J Am Coll Cardiol. 26:1995;1615-1622.
16. Andrews T.C., Whitney E.J., Green G., Kalenian R., Personius B.E. Effect of gemfibrozil ± niacin ± cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl. Am J Cardiol. 80:1997;831-835.
17. Joannides R., Haefeli W.E., Linder L., Richard V., Bakkali E.H., Thuillez C., Luscher T.F. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 91:1995;1314-1319.
18. Cohen R.A., Vanhoutte P.M. Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation. 92:1995;3337-3349.
19. Ericsson C.G., Hamsten A., Nilsson J., Grip L., Svane B., de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 347:1996;849-853.
20. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 341:1999;410-418.